SAN DIEGO, July 19 /PRNewswire-FirstCall/ -- Sequenom, Inc. announced today that City of Hope National Medical Center (City of Hope) has purchased Sequenom's MassARRAY genetic analysis system and portfolio of application tools for the Center's molecular marker research and individualized cancer care initiatives.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
"We will utilize Sequenom's platform and applications for quantitative gene expression and methylation (epigenetic) studies. In addition, we will use the high throughput genotyping application as an integral part of our on-going research both to identify individuals at high risk for developing cancer, and to aid in the development of therapeutic modalities based on the unique genetic profile of a given patient," said Garry Larson, Ph.D., Associate Research Scientist, City of Hope. "The MassARRAY platform is unique and particularly well-suited to our needs because it enables us to perform many different types of analysis in a cost-effective manner and on a single platform."
"The National Cancer Institute has designated City of Hope a 'Comprehensive Cancer Center,' one of just a handful of such elite institutions nationwide, and we are excited that their researchers will use the MassARRAY platform for their pioneering cancer studies involving epigenetics," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "Epigenetic analysis has significant clinical potential in cancer research and other fields. Our MassARRAY technology enables this important analysis and will help accelerate advancements in understanding and potentially treating cancer and other diseases."
Other prominent cancer research institutions that have selected Sequenom's MassARRAY technology platform include M.D. Anderson's Kleberg Center and the Roswell Park Cancer Institute.
About City of Hope National Medical Center
Founded in 1913 and located northeast of Los Angeles in Duarte, California, City of Hope is an innovative biomedical research, treatment, and educational institution dedicated to the prevention and cure of cancer and other life-threatening diseases. City of Hope is guided by a compassionate patient-centered philosophy and is supported by a national foundation of humanitarian philanthropy. Through a combination of patient-centered care, state-of-the-art treatment and groundbreaking research, City of Hope is a world-renowned leader in the fight against cancer, diabetes, HIV/AIDS, and other devastating diseases.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for non-invasive prenatal testing, biomedical research, molecular medicine and agricultural applications. The Company's proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the City of Hope National Cancer Center's expected use of the MassARRAY platform and applications, the clinical potential of epigenetic analysis, and acceleration of advancements in understanding and potentially treating cancer and other diseases, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks detailed from time to time in Sequenom's SEC filings, including Sequenom's Annual Report on Form 10-K for the year ended December 31, 2005, and its most recently filed quarterly report on Form 10-Q and subsequent filings. These forward-looking statements are based on current information that is likely to change. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.CONTACT: Clarke Neumann, Investor Relations of Sequenom, Inc.,+1-858-202-9206, cneumann@sequenom.com
Web site: http://www.sequenom.com/
Company News On-Call: http://www.prnewswire.com/comp/124192.html /
